458 related articles for article (PubMed ID: 23512266)
1. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.
Soda Y; Myskiw C; Rommel A; Verma IM
J Mol Med (Berl); 2013 Apr; 91(4):439-48. PubMed ID: 23512266
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
4. Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies.
Boer JC; Walenkamp AM; den Dunnen WF
Crit Rev Oncol Hematol; 2014 Oct; 92(1):38-48. PubMed ID: 24933160
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
Onishi M; Kurozumi K; Ichikawa T; Date I
Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in glioblastoma multiforme: navigating the maze.
Linkous AG; Yazlovitskaya EM
Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499
[TBL] [Abstract][Full Text] [Related]
7. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration.
Bazan NG; Reid MM; Flores VAC; Gallo JE; Lewis W; Belayev L
Cancer Metastasis Rev; 2021 Sep; 40(3):643-647. PubMed ID: 34519960
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
Reardon DA; Wen PY; Desjardins A; Batchelor TT; Vredenburgh JJ
Expert Opin Biol Ther; 2008 Apr; 8(4):541-53. PubMed ID: 18352856
[TBL] [Abstract][Full Text] [Related]
9. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK; Engelhard HH; Lakka SS
Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
[TBL] [Abstract][Full Text] [Related]
10. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
12. Resistance to antiangiogenic therapies.
Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
[TBL] [Abstract][Full Text] [Related]
13. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
[TBL] [Abstract][Full Text] [Related]
14. Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.
Kang W; Kim SH; Cho HJ; Jin J; Lee J; Joo KM; Nam DH
Oncotarget; 2015 Sep; 6(29):27239-51. PubMed ID: 26336988
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapies in the management of glioblastoma.
Schulte JD; Aghi MK; Taylor JW
Chin Clin Oncol; 2021 Aug; 10(4):37. PubMed ID: 32389001
[TBL] [Abstract][Full Text] [Related]
16. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of VEGF in the treatment of glioblastoma.
Robles Irizarry L; Hambardzumyan D; Nakano I; Gladson CL; Ahluwalia MS
Expert Opin Ther Targets; 2012 Oct; 16(10):973-84. PubMed ID: 22876981
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
19. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
Wang N; Jain RK; Batchelor TT
Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
[TBL] [Abstract][Full Text] [Related]
20. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
